Equity Profile

LGND

Ligand Pharmaceuticals Incorporated

Health CarePharmaceuticals$4.7B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ligand Pharmaceuticals Incorporated (LGND) is a healthcare company focused on developing and commercializing technologies that enhance drug discovery and development. With a market cap of $5 billion, Ligand plays a significant role in the pharmaceutical industry, leveraging innovative approaches to improve patient outcomes.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Ligand is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is crucial to assess the company's ability to expand its market presence and drive future profits.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LGND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+287.89%

Avg Stock Reaction

+1.84%

Last Quarter Recap

In Q1-2026, Ligand reported an EPS of $1.63, significantly beating expectations by 66.84%. However, the stock dropped by 9.55% the following day, indicating potential concerns despite the strong earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating another strong earnings report from Ligand, especially given its history of beating EPS estimates. However, the lack of consensus estimates raises uncertainty about revenue expectations.

Bull Case

If Ligand continues its trend of exceeding EPS expectations, it could lead to a positive market reaction, especially if accompanied by strong revenue growth.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to significant downward pressure on the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Ligand's history of EPS surprises, this figure will be critical in determining market sentiment and stock movement.

What is the outlook for revenue growth?

Investors will be keen to understand how Ligand plans to sustain its growth trajectory, especially in light of recent performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Ligand's ability to sustain high EPS growth due to its innovative drug development technologies, which could lead to better-than-expected results.

Supporting Evidence

Ligand has consistently beaten EPS estimates, suggesting strong operational efficiency.

The options market is pricing in a significant move, indicating that traders expect volatility that could favor a positive outcome.

Key Risk

If EPS comes in below $1.50, it could undermine the bullish narrative and lead to a reassessment of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on whether Ligand can maintain its impressive earnings track record and provide a positive outlook for revenue.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.50 would signal a potential downturn and confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.86%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±15.9% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

47.7%

Calls (100)P/C Ratio: 0.15Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ligand beats expectations, history suggests the stock could rise by around 1.84%, confirming the bullish sentiment.

In-Line / Cautious

If results are in line with previous quarters but lack strong guidance, the stock may experience muted movement as investors reassess.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 9.55% following disappointing results.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or partnerships.
2Management's commentary on revenue growth expectations.
3Insights into cost management and operational efficiencies.
4Details on market conditions affecting the pharmaceutical sector.
5Guidance on future earnings and strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Ligand is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is crucial to assess the company's ability to expand its market presence and drive future profits.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LGND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+287.89%

Avg Stock Reaction

+1.84%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Ligand continues its trend of exceeding EPS expectations, it could lead to a positive market reaction, especially if accompanied by strong revenue growth.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to significant downward pressure on the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Ligand's history of EPS surprises, this figure will be critical in determining market sentiment and stock movement.

What is the outlook for revenue growth?

Investors will be keen to understand how Ligand plans to sustain its growth trajectory, especially in light of recent performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Ligand's ability to sustain high EPS growth due to its innovative drug development technologies, which could lead to better-than-expected results.

Supporting Evidence

Ligand has consistently beaten EPS estimates, suggesting strong operational efficiency.

The options market is pricing in a significant move, indicating that traders expect volatility that could favor a positive outcome.

Key Risk

If EPS comes in below $1.50, it could undermine the bullish narrative and lead to a reassessment of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on whether Ligand can maintain its impressive earnings track record and provide a positive outlook for revenue.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.50 would signal a potential downturn and confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.86%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±15.9% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

47.7%

Calls (100)P/C Ratio: 0.15Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ligand beats expectations, history suggests the stock could rise by around 1.84%, confirming the bullish sentiment.

In-Line / Cautious

If results are in line with previous quarters but lack strong guidance, the stock may experience muted movement as investors reassess.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 9.55% following disappointing results.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or partnerships.
2Management's commentary on revenue growth expectations.
3Insights into cost management and operational efficiencies.
4Details on market conditions affecting the pharmaceutical sector.
5Guidance on future earnings and strategic initiatives.